Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for Roche's push into treating rare diseases including hemophilia A.
from Reuters: Company News https://ift.tt/2LZVb8T
via IFTTT
0 comments:
Post a Comment